Qiagen (QGEN) announced the launch of Ingenuity Pathway Analysis Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data. Leveraging AI technology, IPA Interpret helps distill complex differential expression analyses into actionable insights, helping researchers understand which genes are involved in a disease, a biological process or a response to a drug or environmental condition. IPA, which forms the foundation of IPA Interpret, has over 50,000 citations and a high-quality, manually curated knowledge base. This widely recognized platform structures and integrates causal biomedical relationships between genes, diseases, functions, targets, drugs chemicals, and other objects. With IPA’s curated knowledge base, scientists can confidently predict and validate novel target-disease and drug-disease relationships. By combining this extensive knowledge with advanced analyses and AI algorithms, IPA Interpret now automatically analyzes, compares, and contextualizes complex gene expression datasets available in IPA, identifying key biological processes, pathways, and networks, in a streamlined web-page report.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on QGEN:
- Qiagen assumed with Buy from Hold at Jefferies
- Qiagen reports over 1,000 placements of EZ2 Connect instrument
- Qiagen enters three-year partnership with McGill University
- Qiagen price target raised to EUR 46 from EUR 45 at Morgan Stanley
- Qiagen’s Financial Growth and Rising Debt in Q3 2024
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
